Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway

Grace Wakabayashi, Yu Ching Lee, Frank Luh, Chun Nan Kuo, Wei Chao Chang, Yun Yen

研究成果: 雜誌貢獻回顧型文獻

1 引文 斯高帕斯(Scopus)

摘要

Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) demonstrate impressive clinical benefits in clinical trials. In this review, we present background information about therapies involving PD-1/PD-L1 blockade and provide an overview of current clinical trials. Furthermore, we present recent advances involving predictive biomarkers associated with positive therapeutic outcomes in cancer immunotherapy.
原文英語
文章編號96
期刊Journal of Biomedical Science
26
發行號1
DOIs
出版狀態已發佈 - 十二月 5 2019

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)

指紋 深入研究「Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway」主題。共同形成了獨特的指紋。

  • 引用此